{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:21:11Z","timestamp":1767165671526,"version":"build-2238731810"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":2194,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009431","name":"Baxalta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1111\/jth.13440","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:16:46Z","timestamp":1470874606000},"page":"2141-2147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predicting the outcomes of using longer\u2010acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis"],"prefix":"10.1016","volume":"14","author":[{"given":"A.H.","family":"Miners","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.J.","family":"Pasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13440_bb0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0015","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco\u2010Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13440_bb0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia prophylaxis in young patients\u2013a long\u2010term follow\u2010up","volume":"241","author":"Lofqvist","year":"1997","journal-title":"J Intern Med"},{"key":"10.1111\/jth.13440_bb0025","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","article-title":"A United Kingdom Haemophilia Centre Doctors\u2019 Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A","volume":"149","author":"Richards","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13440_bb0030","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1365-2516.2012.02790.x","article-title":"Haemophilia prophylaxis: how can we justify the costs?","volume":"18","author":"Feldman","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13440_bb0040","first-page":"6","article-title":"The need for recombinant factor VIII: historical background and rationale","volume":"28","author":"Hilgartner","year":"1991","journal-title":"Semin Hematol"},{"key":"10.1111\/jth.13440_bb0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2013-10-529974","article-title":"Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A","volume":"123","author":"Mahlangu","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.13440_bb0050","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1517\/14712598.2013.819339","article-title":"Development of long\u2010acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia","volume":"13","author":"Shapiro","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1111\/jth.13440_bb0055","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1182\/blood-2011-09-382846","article-title":"Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients","volume":"119","author":"Powell","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.13440_bb0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/asheducation-2013.1.37","article-title":"Long\u2010lasting recombinant factor VIII proteins for hemophilia A","volume":"2013","author":"Shapiro","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/jth.13440_bb0065","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"10.1111\/jth.13440_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W","article-title":"Modelling in economic evaluation: an unavoidable fact of life","volume":"6","author":"Buxton","year":"1997","journal-title":"Health Econ"},{"issue":"Suppl. 4","key":"10.1111\/jth.13440_bb0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/hae.12405","article-title":"Changing paradigm of prophylaxis with longer acting factor concentrates","volume":"20","author":"Carcao","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/hae.12766","article-title":"Long\u2010term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A","volume":"22","author":"Nolan","year":"2016","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0085","unstructured":"Berntorp E, Dolan G, Linarij S, Santagostino E, Tosetto A, Alvarez\u2010Roman T, Lopez RP, Oldenburg J, Scholz U, Holmstrom M, Schved JF, Trossaert M, Hermans C, Ludlam C, Lethagen S. A European Retrospective Study of the Current Treatment Practice of Haemophilia A. Presented at: 9th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 3\u20105 Feb, 2016, Malm\u00f6, Sweden."},{"key":"10.1111\/jth.13440_bb0090","unstructured":"Buckley BC, Linvingston TP, Odom T, Krishnan S. Evaluation of Real\u2010world and Clinical Trial\u2010based Dosing of Factor VIII in Hemophilia A Patients. Poster CR16 Presented at: National HemophiliaFoundation 66th Annual Meeting September 18\u201020, 2014 Washington, DC 2014."},{"key":"10.1111\/jth.13440_bb0095","unstructured":"National Hemophilia Foundation. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). MASAC Document #179. Available at: http:\/\/www.hemophilia.org\/NHFWeb\/Resource\/StaticPages\/menu0\/menu5\/menu57\/masac179.pdf. Accessed September 21, 2015."},{"key":"10.1111\/jth.13440_bb0100","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2516.2008.01843.x","article-title":"A survey of adherence to haemophilia therapy in six European countries: results and recommendations","volume":"14","author":"De Moerloose","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/0887044031000098198","article-title":"The illness perceptions and treatment beliefs of individuals with severe haemophilia and their role in adherence to home treatment","volume":"18","author":"Llewellyn","year":"2003","journal-title":"Psychol Health"},{"key":"10.1111\/jth.13440_bb0110","unstructured":"Buckley BC, Hagberg B, Zhou J, Eldar\u2010Lissai A. Adherence to Treatment in Haemophilia: A Comparison of Conventional and Prolonged Half\u2010Life Therapies. Presented at: 9th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 3\u20105 Feb, 2016, Malm\u00f6, Sweden."},{"key":"10.1111\/jth.13440_bb0115","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13440_bb0120","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break\u2010through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13440_bb0125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3111\/13696998.2015.1016228","article-title":"Burden of illness: direct and indirect costs among persons with hemophilia A in the United States","volume":"18","author":"Zhou","year":"2015","journal-title":"J Med Econ"},{"key":"10.1111\/jth.13440_bb0130","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2516.2009.02129.x","article-title":"VERITAS\u2010Pro: a new measure of adherence to prophylactic regimens in haemophilia","volume":"16","author":"Duncan","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2516.2012.02813.x","article-title":"Treatment patterns, health\u2010related quality of life and adherence to prophylaxis among haemophilia A patients in the United States","volume":"18","author":"Duncan","year":"2012","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/hae.12079","article-title":"Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review","volume":"19","author":"Schrijvers","year":"2013","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2516.2010.02370.x","article-title":"Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia","volume":"17","author":"Collins","year":"2011","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0150","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1111\/hae.12718","article-title":"Author's response: \u2018Transition considerations for extended half\u2010life factor products\u2019","volume":"21","author":"Croteau","year":"2015","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0155","first-page":"169","article-title":"Prophylaxis for adults with haemophilia: one size does not fit all","volume":"10","author":"Fischer","year":"2012","journal-title":"Blood Transfus"},{"issue":"Suppl. 4","key":"10.1111\/jth.13440_bb0160","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hae.12425","article-title":"Prophylaxis in real life scenarios","volume":"20","author":"Fischer","year":"2014","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2516.2006.01189.x","article-title":"Practice patterns in haemophilia A therapy \u2013 global progress towards optimal care","volume":"12","author":"Geraghty","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/jth.13440_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/hae.12009","article-title":"Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much?","volume":"19","author":"Miners","year":"2013","journal-title":"Haemophilia"}],"updated-by":[{"DOI":"10.1111\/jth.13645","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000}}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13440","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622033712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622033712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13440\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T20:49:07Z","timestamp":1673815747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622033712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1538783622033712"],"URL":"https:\/\/doi.org\/10.1111\/jth.13440","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting the outcomes of using longer\u2010acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}